News & SEC Filings

View the latest news and SEC filings

News

LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD (tradename of Merck &

Transaction expected to close on October 7, 2025 LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to

Posters support Ohtuvayre ® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on

RAHWAY, N.J. & RALEIGH, N.C.–( BUSINESS WIRE )– MSD (tradename of Merck & Co., Inc., Rahway, N.J. USA) and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a

SEC Filings

Date Form Filing Group

August 27, 2020

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

6-K

Current Reports

August 25, 2020

CORRESP

CORRESP

Other

XLS

August 25, 2020

This filing is a pre-effective amendment to an F-1 filing

F-1/A

Registration Statements

August 25, 2020

Amendment to a previously filed 6-K

6-K/A

Current Reports

August 24, 2020

UPLOAD

UPLOAD

Other

August 20, 2020

Securities offered to employees pursuant to employee benefit plans

S-8

Registration Statements

August 19, 2020

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

6-K

Current Reports

August 17, 2020

Registration statement for certain foreign private issuers

F-1

Registration Statements

August 14, 2020

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

6-K

Current Reports

Developing novel therapeutics for respiratory diseases

Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.

Close up of female doctor hold woman patient hands help on personal therapy session, psychologist or counselor show understanding and care, support depressed suffering client on treatment